Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Review Article

Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies

Author(s): Teruhide Yamaguchi* and Eriko Uchida

Volume 18, Issue 2, 2018

Page: [202 - 208] Pages: 7

DOI: 10.2174/1568009617666170222142650

Price: $65

Abstract

Oncolytic viruses, which include both naturally occurring wild-type viruses/attenuated viruses and genetically modified viruses, have recently been developed for use in innovative cancer therapies. Genetically modified oncolytic viruses possess the unique ability to replicate conditionally as a unique gene therapy product. Since oncolytic viruses exhibit prolonged persistence in patients, viral shedding and transmission to third parties should be major concerns for clinical trials along with the clinical safety and efficacy. Accordingly, studies are now underway to establish the safety and efficacy of oncolytic viruses.

Keywords: Oncolytic virus, gene therapy, cancer therapy, replicating virus, genetically modified viruses, clinical safety and efficacy.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy